Heron Therapeutics, INC /DE/ Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, has filed a Schedule 13G amendment indicating zero beneficial ownership of Heron Therapeutics, Inc. common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Heron Therapeutics Inc. following an internal realignment.
NASDAQ
Clearline Capital LP, Clearline Capital LLC, and Marc Majzner have jointly disclosed a 6.7% beneficial ownership stake in Heron Therapeutics, Inc.
NASDAQ
The Vanguard Group reported a 5.35% beneficial ownership stake in Heron Therapeutics Inc. common stock as of December 31, 2025.
NASDAQ
Clearline Capital LP, Clearline Capital LLC, and Marc Majzner have jointly disclosed a beneficial ownership of 5.3% in Heron Therapeutics, Inc. common stock.
NASDAQ
SCHEDULE: Vanguard Amends Heron Therapeutics Stake
The Vanguard Group has filed an amendment to its Schedule 13G, reporting a 4.61% beneficial ownership stake in Heron Therapeutics Inc.